Golden Leaf Holdings Reports Fiscal First Quarter 2020 Results

Q1 Financial Highlights:

  • Record quarterly revenues from continuing operations of $4.7M, an increase of 21% compared to the first quarter of 2019 and 34% compared to the fourth quarter of 2019. This increase was led by record first quarter Chalice Farms retail revenues of $3.1M which was driven by an increase in total tickets of 19% compared to the first quarter of 2019 and 7% compared to the fourth quarter of 2019.
  • Adjusted EBITDA loss of $0.9M, an improvement of $1.1M, or 55%, year-over-year, and an improvement of $1.3M, or 59%, compared to the 2019 run rate adjusted EBITDA
  • Gross profit of $1.7M was a 21% improvement from gross profit of $1.4M from same period 2019.
  • Lowered operating expenses to $3.3M, a reduction of $1.2M, or 26% year over year

“The Company continues to take a more disciplined approach to growth and working capital utilization, resulting in better supply chain control in purchasing, inventory management and production,” continued Yapp. “We have extended terms with vendors, dramatically improved warehouse efficiencies and collections, reduced receivables, and cut operating expenses.”

Q1 Business Highlights:

  • On January 8, 2020, the Company launched a full-spectrum version of the popular Rick Simpson cannabis oil extracts, the RXO product line, utilizing Essential Innovations patented technology.
  • As reported on February 3, 2020, the Company announced it had entered into an agreement to acquire Tozmoz, LLC, one of Oregon’s premier cannabis extractors. On March 20, 2020, the Company accelerated the launch of home delivery service in preparations for the upcoming concerns of COVID-19 in Oregon. Both Powell and Country Store retail locations offer this service, with more stores coming soon. On March 23, 2020 Governor Kate Brown announced a “Stay Home, Stay Healthy” order closing all non-essential businesses. Being considered essential, our retail stores began practicing social distancing, increased cleaning regiments, and continued to service our customers in a safe and healthy way.
  • On March 13, 2020, the Company signed a Product Manufacturing and Distribution Agreement with Sugar Pine (i.e., A New Leaf Production Center, LLC, a Nevada limited liability company) to produce marijuana-infused products for the Company under Nevada law, for sale and distribution in Nevada.
  • Beginning March 23, 2020, launched curbside pickup at our retail stores to limit crowds, placing more emphasis on online ordering.

Fiscal First Quarter Ended March 30, 2020 Financial Results

For the three months ended March 31, 2020 (“Q1 2020”), total revenue from continuing operations was $4.7 million, as compared to $3.9 million for the same period in 2019 (“Q1 2019”). The 19% year-over-year increase largely reflects improvements in the Oregon retail and wholesale businesses. Gross profit was $1.7 million, or 37% of total revenue for Q1 2020, compared with $1.4 million, or 37% of total revenue, in Q1 2019.

Operating expenses were $3.3 million for Q1 2020, compared with $4.4 million in Q1 2019, an improvement of $1.1 million, or 26%. Cash-based operating expenses of $2.6 million in Q1 2020 were 53% of total revenue, compared with $3.4 million in Q1 2019, or 87% of total revenue. The reduction in operating expenses was due primarily to decreased salaries, wages, and share-based compensation and more significant than the cost reduction measures that were taken in Q1 2019.

Adjusted EBITDA loss was $0.9 million for Q1 2020, compared with a loss of $2.0 million for Q1 2019, a 55% improvement. This measure is primarily driven by the increase in gross profit and the reduction in cash-based operating expenses for the period. The Company considers Adjusted EBITDA an important operational measure for the business. Net loss from continuing operations for Q1 2020 was $2.5 million, compared to $3.1 million for Q1 2019, driven primarily by increased gross profit. See the management discussion and analysis for Q1 2020 as filed on SEDAR for a description of Adjusted EBITDA.

As of March 31, 2020, the Company offers, directly and through its partners, over 100 SKUs across 13 product lines in three jurisdictions: Oregon, California, and Nevada.

About Golden Leaf Holdings

Golden Leaf Holdings is a premiere consumer-driven cannabis company specializing in production, processing, wholesale, distribution and retail, with seven dispensaries in Portland, Oregon. The Company is committed to developing a dynamic portfolio built around the recognized brands of Chalice Farms, with a focus on health and wellness.  Markets served include Oregon, California, Nevada and Washington. Visit for regular updates.

Investor Relations:

John Varghese
Executive Chairman
Golden Leaf Holdings Ltd.

Disclaimer: This press release contains “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the Company’s future business operations, the opinions or beliefs of management and future business goals. Generally, forward looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information. These risks include but are not limited to general business, economic and competitive uncertainties, regulatory risks, market risks, risks inherent in manufacturing and retail operations such as unforeseen costs and production shutdowns, difficulties in maintaining brand loyalty, and other risks of the cannabis industry. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward looking information. Forward-looking information is provided herein for the purpose of presenting information about management’s current expectations relating to the future and readers are cautioned that such information may not be appropriate for other purpose. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws. This press release does not constitute an offer of securities for sale in the United States, and such securities may not be offered or sold in the United States absent registration or an exemption from registration or an exemption from registration.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.

Interim Condensed Consolidated Statement of Financial Position (Unaudited)
As at March 31, 2020 and December 31, 2019
(Expressed in U.S. dollars)
    March 31, 2020   December 31, 2019
Cash   $ 1,543,102     $ 3,531,202  
Accounts receivable Note 6   259,424       167,178  
Other receivables Note 6   452,273       447,901  
Income tax recoverable     6,497       74,034  
Sales tax recoverable     283,331       271,866  
Biological assets Note 8   183,928       88,078  
Inventory Note 8   3,705,769       2,965,304  
Prepaid expenses and deposits     558,469       325,329  
Total current assets     6,992,793       7,870,892  
Property, plant and equipment Note 9   3,412,671       3,723,489  
Notes receivable Note 7   919,488       919,488  
Right-of-use assets, net Note 10   4,400,294       4,333,064  
Intangible assets Note 11   10,737,423       10,737,423  
Goodwill Note 11   4,056,172       4,056,172  
Total assets     30,518,841       31,640,528  
Accounts payable and accrued liabilities     2,135,555       1,564,982  
Interest payable     304,699       125,900  
Income taxes payable     314,789        
Deferred income tax payable     248,852       248,852  
Sales tax payable     11,282       187,520  
Current portion of long-term debt Note 13   76,173       82,404  
Lease liability Note 13   920,877       843,238  
Total current liabilities     4,012,227       3,052,896  
Long term debt Note 13   29,952       29,952  
Long term lease liability Note 13   4,185,920       4,090,806  
Convertible debentures carried at fair value Note 12   4,706,141       4,706,141  
Consideration payable – cash portion Note 13   4,286,978       4,218,866  
Consideration payable – equity portion Note 13   4,897,507       4,940,667  
Total liabilities     22,118,725       21,039,328  
Share capital Note 14   147,873,002       147,763,499  
Warrant reserve Note 15   1,553,850       1,980,217  
Share option reserve Note 16   4,082,010       4,181,350  
Contributed surplus     59,940       59,940  
Deficit     (145,168,686 )     (143,383,806 )
Total shareholders’ equity     8,400,116       10,601,200  
Total liabilities and shareholders’ equity   $ 30,518,841     $ 31,640,528  
Interim Condensed Consolidated Statements of Operations and Comprehensive Gain (Loss) (Unaudited)
For the three months ended March 31, 2020 and 2019
(Expressed in U.S. dollars)
    For the three months ended March 31,
     2020    2019
Product sales Note 21 $ 4,239,582     $ 3,728,959  
Consulting revenue Note 21   430,722       202,070  
Total Revenue     4,670,304       3,931,029  
Inventory expensed to cost of sales Note 8, 21   2,964,192       2,364,969  
Production costs Note 21   0       128,577  
Gross margin, excluding fair value items     1,706,112       1,437,484  
(Gain) loss on changes in fair value of biological assets Note 8, 21   (20,714 )      
Gross profit     1,726,826       1,437,484  
General and administration     2,045,274       2,774,831  
Share based compensation Note 16   129,579       411,926  
Sales and marketing     535,026       628,685  
Depreciation and amortization Note 9   568,345       630,849  
Total expenses     3,278,224       4,446,291  
Loss before items noted below     (1,551,398 )     (3,008,807 )
Interest expense     551,101       731,001  
Transaction costs           6,108  
Loss (gain) on disposal of assets Note 9   7,822       (16,945 )
Other income     (28,438 )     (141,197 )
Gain on change in fair value of warrant liabilities           (499,662 )
Gain on change in fair value of convertible debentures Note 12         (36,169 )
Loss before income taxes     (2,081,883 )     (3,051,943 )
Current income tax expense     358,283       11,624  
Net loss from continuing operations   $ (2,440,166 )   $ (3,063,567 )
Income from discontinued operations Note 7         17,524  
Net loss   $ (2,440,166 )   $ (3,046,043 )
Other comprehensive loss        
Items that will be reclassified subsequently to profit or loss:        
Cumulative translation adjustment           892,214  
Comprehensive loss   $ (2,440,166 )   $ (3,938,257 )
Basic and diluted loss per share from continuing operations   $ (0.00 )   $ (0.01 )
Basic and diluted loss per share from discontinued operations   $     $ 0.00  
Weighted average number of common shares outstanding     859,890,063       534,900,058  
Adjusted EBITDA      
  For the three months ended
  March 31, 2020 March 31, 2019
Loss before income taxes   (2,081,883 )     (3,051,943 )
Net impact, fair value of biological assets   (20,714 )      
Depreciation and amortization   568,345       630,849  
Fair value changes on debt and equity instruments         (535,831 )
Share based compensation   129,579       411,926  
Interest expense, net   551,101       731,001  
Transaction costs         6,108  
Impairments and other   (28,438 )     (141,197 )
Loss on disposal   7,822       (16,945 )
Adjusted EBITDA loss $ (874,188 )   $ (1,966,032 )

Subscribe to Our News